Highlights Hubei Biocause Pharmaceutical Co., Ltd.

Equities

000627

CNE000000F48

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-06-03 pm EDT			5-day change	1st Jan Change
2.08 ^CNY	+1.96%		-6.73%	-26.76%

Apr. 29	Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 15	Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Hubei Biocause Pharmaceutical Co., Ltd. agreed to acquire 60% stake in Huarui Insurance Sales Co.,Ltd. for approximately CNY 150 million.	23-09-21	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Hubei Biocause Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payable on 30 May 2023	23-05-22	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Hubei Biocause Pharmaceutical Co., Ltd. Announces Final Profit Distribution Proposal for 2022	23-04-24	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Hubei Biocause Pharmaceutical Gets Regulatory Nod for Ibuprofen; Shares Down 5%	22-12-30	MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Biocause Heilen Pharma to Unlock 1.21% Restricted Stake	22-06-19	MT
Hubei Biocause Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021, Payable on June 2, 2022	22-05-24	CI
Hubei Biocause Pharmaceutical Co., Ltd. Proposes Cash Dividend for 2021	22-05-05	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Hubei Biocause’s Pharmaceutical Ingredients Unit Surges 64% in Shenzhen Debut	21-12-21	MT
Hubei Biocause’s Pharmaceutical Ingredients Unit Targets $243 Million in Shenzhen IPO	21-12-09	MT
Hubei Biocause’s Pharmaceutical Ingredients Unit Launches Shenzhen IPO	21-12-02	MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Hubei Biocause Pharmaceutical Co., Ltd.

Equities

000627

CNE000000F48

Highlights

Filters